Eli Lilly and Company, a global healthcare leader, announced results
from its non-clinical study in genetically engineered mice examining
combination therapy with the murine version of the beta-amyloid antibody
N3pG and beta-secretase inhibitor BACE (LY2811376). Data results found
that combination therapy was more effective in removing clumps of
amyloid-beta protein in the brain - a component that is thought to lead
to Alzheimer's disease (AD) - than use of one therapy.
These data were presented at the Alzheimer's Association International Conference 2014 (AAIC 2014) in Copenhagen, Denmark by Ron DeMattos, Ph.D., research fellow in the Neuroscience Division at Eli Lilly and Company. The data was also featured by the AAIC in a research media tips sheet.
These data were presented at the Alzheimer's Association International Conference 2014 (AAIC 2014) in Copenhagen, Denmark by Ron DeMattos, Ph.D., research fellow in the Neuroscience Division at Eli Lilly and Company. The data was also featured by the AAIC in a research media tips sheet.
No comments:
Post a Comment